FDA approves Advanced Accelerator's drug for digestive tract cancer

Jan 26 (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved French drugmaker Advanced Accelerator Application SA's drug to treat patients with a type of digestive tract cancer.

The FDA said the drug, Lutathera, was approved to treat a type of cancer affecting a gastrointestinal tract.

Swiss biotech Novartis AG agreed in October to buy Advanced Accelerator in a $2.9 billion deal. (Reporting by Manas Mishra in Bengaluru; editing by Sai Sachin Ravikumar)